Embody GLP-1 Review vs PlexusDx (2026)

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

If you’re researching Embody GLP-1 reviews, the headline pricing is the part most write-ups bury the lead on. Embody (joinem.co, operated by Modern Metabolic Medicine, Inc.) advertises a $99 or $149 introductory month, then locks refills at $299/month for compounded semaglutide. Tirzepatide starts at $199/month and a needle-free GLP-1 gum is listed at $149–$199/month. Branded Ozempic, where it’s offered, is $1,498/month. This review pressure-tests Embody’s real annualized cost, the compounded-vs-FDA-approved medication question, the refund and cancellation rules most reviews skip, and where PlexusDx Semaglutide Injection, Tirzepatide Injection, and Microdose GLP-1 Protocol sit relative to Embody on price, oversight, and whether genetics inform your dose before week one.

Embody at a glance — the verified specs

Embody is a cash-pay GLP-1 telehealth platform with a published refund policy, a named board-certified CMO (Dr. Alan Viglione, MD), a LegitScript badge, and a pharmacy network managed by OpenLoop. Treatment decisions are made by clinicians affiliated through CareGLP Affiliated P.C.s; Embody itself is the technology platform, not the prescribing clinician or dispensing pharmacy. Plans are month-to-month with no contract; cancellation must be submitted at least 72 hours before the next billing date. HSA and FSA cards are accepted; insurance is not. Embody states GLP-1 access in all 50 states, though their terms of service describe service in “certain states” — confirm your eligibility during intake. Most patients are prescribed compounded semaglutide or tirzepatide; compounded medications are not FDA-approved finished drug products. For a head-to-head reference point, the PlexusDx Weight Management Protocols are also cash-pay, no membership, available across all 50 states (five require a scheduled live consultation), with all-inclusive monthly pricing that covers the async provider consultation, prescription, compounded medication, and shipping in one bill.

The real Embody pricing — first month vs. ongoing

The promotional landing page features as low as $99 for the first month; the main FAQ shows $149 for the first month on semaglutide. After the introductory month, semaglutide refills lock at $299/month. Tirzepatide is listed from $199/month and the GLP-1 gum from $149–$199/month. Branded Ozempic, when prescribed, is $1,498/month. Run the math at the standard semaglutide tier: $149 month one + $299 × 11 = $3,438/year. For comparison, the PlexusDx Microdose GLP-1 Protocol at $129/mo flat is $1,548/year all-in — less than half the Embody semaglutide annualized cost. PlexusDx Semaglutide Injection at $149/mo is $2,148–$2,748/year, and PlexusDx Tirzepatide Injection at $249/mo is $2,748–$3,708/year. PlexusDx also offers GLP-Squared, a compounded semaglutide + tirzepatide dual-compound protocol at $249/mo. Embody’s ongoing rate is not the cheapest in the compounded-GLP-1 market, and that’s the trade-off the $99 promo page tends to obscure.

Compounded vs FDA-approved — what Embody actually dispenses

Most patients on Embody receive compounded semaglutide or tirzepatide prepared by a licensed U.S. compounding pharmacy through the OpenLoop network. Compounded semaglutide and tirzepatide are not FDA-approved finished drug products; they are pharmacy-prepared versions of the same active ingredients found in Wegovy, Ozempic, Mounjaro, and Zepbound. Branded Ozempic appears to be available through Embody at $1,498/month for patients who specifically want the FDA-approved finished product. PlexusDx Weight Management Protocols also use compounded semaglutide and tirzepatide from licensed U.S. compounding pharmacies — same regulatory framework as Embody’s primary path — with four delivery formats: weekly injection, daily oral tablet, microdose troche/capsule/lozenge/sublingual, and dual-compound stacks. The substantive distinction between compounded and branded is FDA-approval status of the finished product, supply consistency, and which regulatory framework governs the medication — not the active ingredient itself.

Safety, side effects, and the boxed warning

The GLP-1 receptor agonist class (semaglutide) and the GIP/GLP-1 dual agonist class (tirzepatide) share a well-characterized side-effect profile: nausea, vomiting, diarrhea, constipation, abdominal pain, and headache are common; pancreatitis, gallbladder disease, and acute kidney injury are less common but documented. The boxed warning for thyroid C-cell tumors applies to both semaglutide and tirzepatide based on rodent studies — this is not specific to any one platform. Embody routes prescribing through licensed U.S. clinicians and a compounding pharmacy network; PlexusDx routes through licensed U.S. clinicians and licensed U.S. compounding pharmacies. The clinical-oversight model is similar at the prescribing layer. The differentiator at PlexusDx is the optional Precision Peptide Genetic Test, which gives the prescribing clinician a genetic baseline before titration — a stratification step Embody does not perform.

Refunds, cancellation, and what 24/7 support actually means

Embody’s refund policy says you receive a full refund if a provider determines you are not medically eligible for treatment. Cancellation is month-to-month with no contract, but must be submitted at least 72 hours before the next billing date to avoid being charged for the next cycle. Embody’s site references a “pause or adjust at any time” option; the specifics of pause-vs-cancel are not detailed in the published policy, so confirm the process with their support team. The 24/7 care team access is included in the monthly fee — one of Embody’s strongest features in the segment — and dose adjustments and medication switches (semaglutide to tirzepatide, for example) are at no additional cost. PlexusDx is also cash-pay with no membership and no contract; the all-inclusive monthly fee covers the async provider consultation, prescription, compounded medication, and shipping. Five states require a scheduled live consultation rather than async intake.

Why genetics matter before you choose a GLP-1 provider

GLP-1 response varies meaningfully across patients. Variants in GLP1R (the GLP-1 receptor itself), GIPR (the GIP receptor relevant to tirzepatide’s dual-agonist mechanism), FTO (appetite regulation), MC4R (satiety signaling), and TCF7L2 (insulin response) are associated with measurably different response patterns to semaglutide and tirzepatide. The Precision Peptide Genetic Test maps 48 unique genes and 57 genetic variants across 14 health pathways — including 34 weight-management insights and the GIPR rs1800437 variant linked to differential GLP-1 response — so the prescribing clinician knows whether a faster-than-typical titration, a slower one, or a tirzepatide-first approach is more likely to fit your biology before week one. The test is $298 standalone or $99 as an add-on after your first month on any PlexusDx protocol. Embody does not include this step; titration is started from a population-average schedule and adjusted on subjective tolerability over the first 8–12 weeks. If you’ve previously tried a GLP-1 and didn’t respond, the genetic baseline is the most useful single input before choosing a second protocol.

Embody vs PlexusDx — a four-question decision frame

Question 1: Are you cash-pay with price as the dominant factor? Compare Embody’s ~$3,438/year semaglutide tier to PlexusDx Microdose GLP-1 Protocol at $1,548/year or Semaglutide Injection at $2,148–$2,748/year. Question 2: Do you want needle-free or oral options? Embody offers a GLP-1 gum; PlexusDx offers Semaglutide Oral ($209+/mo, six dose levels) and Tirzepatide Oral ($279/mo, seven dose levels) plus the microdose troche/capsule/lozenge/sublingual variants. Question 3: Do you want a dual-compound option? PlexusDx GLP-Squared pairs compounded semaglutide and tirzepatide across six dose levels at $249/mo. Question 4: Do you want a genetic baseline informing your titration before the first injection? PlexusDx is the option in this comparison that includes the Precision Peptide Genetic Test in the protocol pathway. If your insurance reliably covers Wegovy or Zepbound at a low copay, neither Embody nor PlexusDx beats branded-with-coverage on cost — both are cash-pay paths.

Frequently asked questions

Is Embody legit and safe?

Embody is a real telehealth platform with LegitScript certification, a named board-certified CMO (Dr. Alan Viglione, MD), a published refund policy, and a licensed pharmacy network through OpenLoop. PlexusDx is also cash-pay, all 50 states (five require a live consult), and uses licensed U.S. compounding pharmacies. Both are platforms; the prescribing clinician makes treatment decisions in either case.

How much does Embody cost after the first month vs PlexusDx?

Embody locks semaglutide refills at $299/month after the introductory month, which annualizes to roughly $3,438/year. PlexusDx Microdose GLP-1 Protocol is $129/mo flat ($1,548/year), Semaglutide Injection is $149/mo, and Tirzepatide Injection is $249/mo. PlexusDx is meaningfully cheaper at the entry tier and competitive at the higher tiers.

Does Embody use compounded or FDA-approved semaglutide?

Embody’s primary offering is compounded semaglutide and tirzepatide, which are not FDA-approved finished drug products. Branded Ozempic is available at $1,498/month. PlexusDx Weight Management Protocols also use compounded semaglutide and tirzepatide from licensed U.S. compounding pharmacies; the regulatory framework is the same as Embody’s primary path.

Can I use HSA or FSA with Embody or PlexusDx?

Embody accepts HSA and FSA cards. PlexusDx is cash-pay; check with your HSA/FSA administrator on individual eligibility for compounded medications, as policies vary. Neither program accepts insurance directly.

Is Embody available in all 50 states?

Embody’s FAQ states GLP-1 access in all 50 states; their terms of service mention service in “certain states.” Confirm your state during intake. PlexusDx Weight Management Protocols are available in all 50 states, with five states requiring a scheduled live consultation rather than async intake.

What if Embody’s semaglutide isn’t working for me?

Embody allows medication switches (semaglutide to tirzepatide) at no additional cost. PlexusDx offers six protocols spanning four mechanism classes — semaglutide, tirzepatide, microdose, and dual-compound — and pairs them with the optional Precision Peptide Genetic Test ($99 add-on after month one) so the next protocol choice is informed by GLP1R, GIPR, FTO, MC4R, and TCF7L2 variants rather than another round of trial-and-error.

What are the most common GLP-1 side effects to expect?

Nausea, vomiting, diarrhea, constipation, abdominal pain, and headache are common across the GLP-1 class and typically improve over the first 4–8 weeks with proper dose titration. Pancreatitis and gallbladder disease are less common but documented. The boxed warning for thyroid C-cell tumors applies to both semaglutide and tirzepatide based on rodent studies; discuss any personal or family history of medullary thyroid carcinoma or MEN 2 with your prescribing clinician.

Embody GLP-1 Review vs PlexusDx (2026): Cost, Safety & Who It Fits | PlexusDx